A novel, blood-based test developed using fragmentomic features of cell-free DNA (cfDNA) detects colorectal cancer (CRC) with a 90.4% sensitivity and shows consistent performance across stages and ...

Colonoscopy conducted beyond 3 months and up to 24 months after a positive fecal immunochemical test are not linked to an ...

Special Report: Rhythm Biosciences surged more than 30% on Friday after confirming the commercial launch of its ColoSTAT ...

TheFly reported on December  17 that Mizuho analyst Anthony Petrone maintained an Outperform rating on GH and raised the ...

A new, highly accurate testing service that improves the early-stage detection of bowel cancer with strong clinical validity will be available in the UK within the next few weeks. The service ...

Cases of colorectal cancer in younger adults are climbing worldwide, driven by lifestyle changes and inherited genetic risks.

The recommendation by the Constitutional Review Committee to extend Ghana’s presidential term from four to five years has ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based ...

“Authorization of our full screening portfolio by the Egyptian Drug Authority represents a milestone in expanding access to early detection in a region with growing chronic disease and cancer burdens, ...

Natera recently reported multiple clinical data readouts, including JAMA Oncology publication of the phase III CALGB/SWOG 80702 trial, showing that adding celecoxib to standard chemotherapy cut ...

The global market for Gastrointestinal Diagnostics was valued at US$4.9 Billion in 2024 and is projected to reach US$5.8 Billion by 2030, growing at a CAGR of 2.8% from 2024 to 2030. This ...